Psychedelic and ketamine research trials in the Czech Republic
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
3 registered studies are counted in the Czech Republic. By compound: 1 psilocybin, 1 MDMA, 1 DMT, 1 5-MeO-DMT and 1 ketamine. By registry status: 2 completed and 1 status not reported. By phase: 3 phase 2. Reported start years run from 2020 (earliest) to 2023 (latest). Studies are linked to 3 institutions.
Country is taken from the research site linked to each registry record. A study counts once, and a study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
Recruiting now
None of the 3 counted studies in the Czech Republic is listed in the registry as recruiting or not yet recruiting as of 11 October 2026. Status is reported by study teams and can be out of date.
At a glance
- 3 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 1 |
| MDMA | 1 |
| DMT | 1 |
| 5-MeO-DMT | 1 |
| Ketamine | 1 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Completed | 2 | 67% |
| Status not reported | 1 | 33% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 2 | 3 | 100% |
When studies started
| Start year | Studies |
|---|---|
| 2020 to 2023 | 3 |
All counted studies
All 3 counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| A Trial of GH001 in Patients With Treatment-resistant Depression | NCT05800860 | Completed | Phase 2 | 2023-05-24 | GH Research Ireland Limited, Pilsen |
| Psilocybin Versus Ketamine in Treatment-Resistant Depression | NCT05383313 | Status not reported | Phase 2 | 2021-05-01 | National Institute of Mental Health, Czech Republic, Klecany |
| Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study | NCT04030169 | Completed | Phase 2 | 2020-06-24 | MAPS Europe B.V., Klecany |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | DMT | 5-MeO-DMT | Ketamine
Condition hubs
Condition hubs that include studies counted in this country, with the number of those studies. Conditions are matched by keyword on registered titles, so one study can appear under more than one condition.
| Condition hub | Studies in this country |
|---|---|
| Depression | 2 |
| Treatment-resistant depression | 2 |
| Post-traumatic stress disorder | 1 |
Other country hubs
United States | Canada | Switzerland | United Kingdom | France | Israel | Brazil | China | Netherlands | Australia | Austria | Germany | Spain | Sweden | Argentina | Belgium | Egypt | Mexico | Poland | Taiwan | Ireland | Denmark | Finland